UPDATE: Phase 1 Trial of HSK46575, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer

HSK46575, a novel CYP11A1 inhibitor designed to suppress the entire steroidogenesis pathway, continues to generate interest in advanced prostate cancer, with new early-phase clinical data providing a clearer picture of its activity and tolerability in patients.

At the latest data cut-off, 27 patients with advanced prostate cancer had been treated across dose-escalation cohorts ranging from 3 to 30 mg. Among evaluable patients, a PSA decline of at least 50% (PSA50) was observed in 30.8% (8 out of 26), indicating a measurable antitumor signal in a heavily pretreated population. While this level of activity may appear modest in unselected cohorts, a more nuanced interpretation emerges when stratifying by androgen receptor (AR) status.

Consistent with prior experience from the CYP11A1 inhibitor class, responses were notably enriched in patients harboring AR ligand-binding domain mutations. These patients demonstrated higher PSA response rates compared to those with AR wild-type disease, reinforcing the biological rationale that tumors with altered AR signaling remain particularly dependent on residual or intracrine steroid production. In contrast, activity in AR wild-type patients was present but less pronounced, underscoring a key limitation of steroidogenesis blockade as monotherapy in the broader CRPC population.

From a safety perspective, HSK46575 appears manageable and potentially favorable relative to expectations for a pan-steroid synthesis inhibitor. Treatment-related adverse events were reported in 63.0% of patients, but only 7.4% experienced Grade 3 or higher events. Importantly, no dose-limiting toxicities or treatment-related deaths were observed during dose escalation. This safety profile is particularly relevant given the mechanism of action, which inherently suppresses glucocorticoids, mineralocorticoids, and sex steroids, raising concerns about tolerability that, so far, have not translated into prohibitive toxicity in the clinical setting.

The broader implication of the data lies in its role as a backbone for combination strategies. Given its upstream and comprehensive suppression of steroidogenesis, HSK46575 may enhance the efficacy of therapies targeting complementary vulnerabilities, a hypothesis already supported by strong preclinical synergy with chemotherapy, PARP inhibition, and epigenetic modulation.

Source.